Chonluten (20mg Vial) Dosage Protocol
Khavinson lung/bronchial short-peptide bioregulator (EDG) — research-only; not approved, benefits unproven.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Chonluten · 20 mg
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).
Typical daily range: 250–1,500 mcg once daily, raised gradually over an 8–16 week course.
Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe (1 unit = 0.01 mL). Convert any dose with units = mcg ÷ 66.7.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Why Chonluten draws research interest
These are the directions researchers and the peptide community most often explore Chonluten for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Lung & bronchial support
Sought as a Khavinson lung bioregulator (EDG); studied in preclinical models of respiratory and bronchial tissue function.
Oxidative-stress & antioxidant research
Investigated in animal-only research for antioxidant activity (e.g., SOD-related pathways) in lung tissue exposed to hypoxic or toxic stress.
Respiratory inflammation & immunity
Explored in preclinical research on inflammatory and immune responses within bronchopulmonary tissue; not approved, benefits unproven.
Longevity & bioregulation
Researched as a short-peptide bioregulator within Khavinson aging and tissue-regulation studies; research-only, investigational.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Chonluten is a synthetic tripeptide (Glu-Asp-Gly, also written EDG and called “T-34”) from the Khavinson cytomax / cytogen class of short-peptide bioregulators, proposed to act on the bronchopulmonary system[1][2]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine, and its proposed benefits are unproven in humans — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 20 mg vial → ~6.67 mg/mL (6,667 mcg/mL).
250–1,500 mcg once daily, titrated gradually across an 8–16 week course.
At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg; 500 mcg ≈ 7.5 units and 1,000 mcg ≈ 15 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: one subcutaneous injection each day, titrating up as tolerated. The wider range cited in research reports spans roughly 250–4,000 mcg/day (250 mcg = 3.75 u, 500 mcg = 7.5 u, 1,000 mcg = 15 u, 1,500 mcg = 22.5 u, 2,000 mcg = 30 u, 3,000 mcg = 45 u, 4,000 mcg = 60 u)[3][4]. These figures come from reference protocols, not from approved human dosing.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 20 mg vial in 3.0 mL gives ~6.67 mg/mL, so 1 unit on a U-100 syringe equals about 66.7 mcg. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with gradual titration.
A 20 mg vial covers roughly 20–40 days at typical 0.5–1 mg/day dosing, so plan a few vials per course.
- 8 weeks: ~2 vials
- 12 weeks: ~3 vials
- 16 weeks: ~4 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 20 mg vial for reconstitution.
- 8 weeks (8 vials): ~24 mL → 3 bottles
- 16 weeks (16 vials): ~48 mL → 5 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.
- ▪Goal (proposed): A bronchopulmonary short-peptide bioregulator studied for effects on bronchial epithelium — proposed in in-vitro and animal models only, not established in humans[5][6].
- ▪Schedule: Daily subcutaneous injections for 8–16 weeks.
- ▪Dose Range: 250–1,500 mcg per day with gradual titration (wider reported range 250–4,000 mcg/day).
- ▪Reconstitution: 3.0 mL bacteriostatic water per 20 mg vial gives ~6.67 mg/mL for accurate unit measurements.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A suggested daily titration approach based on common reference doses.
- ▪Start: Begin at 250 mcg once daily to gauge tolerability.
- ▪Titrate: Increase stepwise (e.g. 250 → 500 → 1,000 mcg) every couple of weeks as tolerated.
- ▪Target: Reach about 1,000–1,500 mcg daily by weeks 5–16.
- ▪Cycle Length: Typically 8–16 weeks.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Chonluten is not FDA- or EMA-approved; as an unapproved substance it falls under WADA category S0 and is not approved for human administration[10].
How This Works
Chonluten is a synthetic tripeptide (Glu-Asp-Gly / EDG, also called “T-34”) in Khavinson’s cytomax / cytogen class of short-peptide bioregulators, proposed to act on the bronchopulmonary system and bronchial epithelium[1][2]. This proposed tissue-specificity comes from short-peptide bioregulator research, not from established human pharmacology.
Its proposed mechanism is regulation of gene expression — reports describe effects on c-Fos, HSP70 and SOD together with an anti-inflammatory signal. It is important to be clear that this mechanism comes from in-vitro and animal models and is not established human pharmacology[3][4].
As a small tripeptide, EDG also faces rapid proteolysis and poor bioavailability[5], which limits how far cell-model findings can be assumed to translate to a living organism[6].
Important caveat: the evidence base for Chonluten is weak. Nearly all of it comes from the originating Russian institute and is dominated by cell and animal studies; the limited human reports are small, uncontrolled and unreplicated. “Lung rejuvenation,” anti-aging and organ-repair claims are not established and should be read as hypotheses, not facts. (Note: Chonluten is the EDG bronchopulmonary tripeptide — it is not a cartilage or collagen extract, a confusion seen in one unreliable source.)
Chonluten is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
Habits that may support recovery alongside the protocol.
- ▪Nutrition: Maintain a balanced diet to support general respiratory and overall health.
- ▪Activity & rest: Pair appropriate activity with real recovery time and avoid environmental respiratory irritants such as smoke.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What in-vitro and animal literature describe; human evidence is very limited, unreplicated and individual results vary.
Potential Benefits
- ▪Bronchopulmonary signalling (preclinical): Cell and animal studies report effects on bronchial-epithelium gene expression and an anti-inflammatory signal[3][4].
- ▪Gene-expression markers (in-vitro): Reports describe changes in c-Fos, HSP70 and SOD in cell models — mechanistic observations, not clinical outcomes[5].
- ▪Tolerability (limited data): Small uncontrolled reports describe general tolerability, with occasional mild injection-site reactions; this is not a safety guarantee.
- ▪Note on humans: These benefits are not established in humans — no adequate, controlled clinical trials of Chonluten have been completed[6].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport restriction: As an unapproved substance, Chonluten falls under WADA category S0 (not approved for human use).
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Khavinson VK et al.Reviews of Khavinson short-peptide bioregulators (cytomax / cytogen class), including the bronchopulmonary tripeptide Chonluten (EDG).
- 2
Khavinson Peptide Bioregulators (Review)Overview of Glu-Asp-Gly (EDG / Chonluten) and proposed tissue-specific (bronchopulmonary) activity in short-peptide bioregulator research.
- 3
In-vitro / Animal Mechanism ReportsCell- and animal-model reports of EDG effects on gene expression (c-Fos, HSP70, SOD) and anti-inflammatory signalling; not human pharmacology.
- 4
Evidence-Quality NoteMost Chonluten evidence originates from a single Russian institute and is dominated by cell/animal studies; human reports are small and unreplicated.
- 5
Gene-Expression Study (in-vitro)In-vitro reports of short-peptide effects on c-Fos / HSP70 / SOD markers in epithelial cell models.
- 6
Khavinson VK et al. (PubMed)No adequate controlled human efficacy trials of Chonluten (EDG) have been completed; benefits remain unproven in humans.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
WADA Prohibited ListWADA category S0 covers substances not approved for human use by any regulatory authority.
- 11
Bronchopulmonary Bioregulator NoteChonluten (EDG) is described as a bronchopulmonary tripeptide bioregulator — not a cartilage or collagen extract.
- 12
Peptide Bioavailability NoteSmall tripeptides such as EDG face rapid proteolysis and poor bioavailability, limiting translation from cell models.
- 13
ClinicalTrials.govNo completed, adequate controlled efficacy trials of Chonluten (EDG) are registered.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesPrime Lab Peptides homepage — research-peptide purity specifications and certificates of analysis.
Chonluten — frequently asked questions
How do I reconstitute a 20 mg vial of Chonluten?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Chonluten?
There is no single correct amount — more water simply spreads the same 20 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Chonluten after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 20 mg vial of Chonluten provide?
Divide the vial strength of 20 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Chonluten approved for human use?
No. Chonluten is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.